A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Umc119-06-05 Intravenous Infusion For The Treatment Of Subjects With Moderate To Severe Chronic Obstructive Pulmonary Disease
Latest Information Update: 17 Jul 2024
At a glance
- Drugs UMC119 06 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Meridigen Biotech
Most Recent Events
- 17 Jul 2024 New trial record